New York, NY, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global lung cancer therapeutics market was valued USD 17.73 billion in 2018 and is expected to generate around USD 42.24 billion by 2025, growing at a CAGR of around 13.2% between 2019 and 2025.
Cancer is a disease caused by an uncontrolled division of abnormal cells in part of the body. These extra cells slowly gather together to form a tissue mass called a tumor. It reduces the lung’s ability to supply oxygen to the lymphatic system and bloodstream. Some leading lung cancer causes are prolonged exposure to asbestos, cigar, cigarette, tobacco intake, pipe-smoking, exposer to pollution, and harmful radiations. The main symptoms of lung cancer are wheezing, coughing, chest pain, appetite loss, shortness of breath, and weight loss.
Browse through 88 Tables & 43 Figures spread over 110 Pages and in-depth TOC on “Global Lung Cancer Therapeutics Market Size 2018: By Type, Size, Share, Industry Trends, Analysis, and Forecast to 2025”.
Request Free Sample Report of Global Lung Cancer Therapeutics Market @ https://www.zionmarketresearch.com/sample/lung-cancer-therapeutics-market
The lung cancer therapeutics market is predicted grow substantially, owing to the growing number of people suffering from lung cancer, rising number of smokers, increasing asbestos exposure, escalating demand for targeted therapies, presence of innovative and efficient drugs, and accelerating unhealthy lifestyle patterns. However, the high cost of drugs, the negative effects of radiation therapies and chemotherapies, and poor cancer diagnostic facilities may limit the lung cancer therapeutics market.
The lung cancer therapeutics market is fragmented based on cancer type, treatment, drug class, end-user, and distribution channel. Based on cancer type, the lung cancer therapeutics market includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 85% of the lung cancers are found to be NSCLC, which will drive this segment in the years ahead.
Request for PDF Brochure of This Report: https://www.zionmarketresearch.com/requestbrochure/lung-cancer-therapeutics-market
By treatment, the lung cancer therapeutics market includes immunotherapy, chemotherapy, targeted therapy, radiation therapy, and others.
Based on drug class, the market is divided into multikinase inhibitors, EGFR inhibitors, alkylating agents, mitotic inhibitors, antimetabolites, and others. Antimetabolites are expected to show the highest CAGR in the future.
Based on end-user, the lung cancer therapeutics market comprises hospitals, homecare, specialty clinics, and others. Homecare is expected to grow rapidly in the years ahead.
Browse the full “Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/lung-cancer-therapeutics-market
Based on the distribution channel, the market for lung cancer therapeutics is categorized into retail pharmacy, hospital pharmacy, internet, and others. Hospital pharmacy is predicted to show the highest CAGR in the future.
North America will dominate the lung cancer therapeutics market over the forecast timeframe, owing to the rising lung cancer occurrences and increasing geriatric population, and growing acceptance of targeted therapy. Additionally, changing lifestyles and growing prevalence of smoking is leading to an escalating number of lung cancer incidences in North America. Additionally, increasing R&D of monoclonal antibodies, technological advancements, the presence of developed healthcare infrastructure, increasing cancer awareness, favorable government initiatives and funding for early cancer diagnosis research are also contributing to this regional market. The U.S. is a major market in North America.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/lung-cancer-therapeutics-market
Europe is predicted to be the second-largest lung cancer therapeutics market, owing to the growing cancer prevalence, favorable government funding in the field of research, analysis, development of innovative medication, presence of developed healthcare infrastructure, favorable reimbursement policies, and technological growth related to cancer. Germany, France, and the U.K. are major countries in the European lung cancer therapeutics market. The U.K. will grow rapidly over the forthcoming years. Germany dominated European lung cancer therapeutics market with a revenue share of about 30% in 2018.
The majority of the revenue of the Asia Pacific lung cancer therapeutics market is generated by the emerging nations of India and China, due to the growing cancer prevalence, large geriatric population base, increasing health awareness, and geographic expansion by major players in developing markets. The market growth is also anticipated to grow, due to the growing awareness related to healthcare. China and Japan are dominant countries in the Asia Pacific lung cancer therapeutics, whereas India is estimated to grow rapidly in the future.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/4617
Latin America is estimated to witness moderate market growth in the future. Brazil contributed the largest revenue share, of about 65%, in 2018 and is a major player in the Latin American lung cancer therapeutics market. The Middle East and Africa lung cancer therapeutics market will register slow growth in the upcoming years, owing to the lack of the latest healthcare infrastructure and advanced technologies across the region.
Some key players of the lung cancer therapeutics market are Pfizer, Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, GlaxoSmithKline, Celgene Corporation, Boehringer Ingelheim, Agennix, AstraZeneca, and Merck & Co.
Request for Discount on This Report: https://www.zionmarketresearch.com/requestdiscount/lung-cancer-therapeutics-market
This report segments the global Lung cancer therapeutics market into:
Global Lung Cancer Therapeutics Market: By Cancer Type
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
Global Lung Cancer Therapeutics Market: By Treatment
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Others
Global Lung Cancer Therapeutics Market: By Drug Class
- Antimetabolites
- Alkylating Agents
- Mitotic Inhibitors
- EGFR Inhibitors
- Multikinase Inhibitors
- Others
Global Lung Cancer Therapeutics Market: By End-User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Lung Cancer Therapeutics Market: By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Internet
- Others
Global Lung Cancer Therapeutics Market: By Region
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Telemedicine Market: https://www.zionmarketresearch.com/report/telemedicine-market
- Pediatric Healthcare Market: https://www.zionmarketresearch.com/report/pediatric-healthcare-market
- Oral Antiseptics Market: https://www.zionmarketresearch.com/report/oral-antiseptics-market
- Smart Implantable Pumps Market: https://www.zionmarketresearch.com/report/smart-implantable-pumps-market
- Dental Bone Graft Substitutes Market: https://www.zionmarketresearch.com/report/dental-bone-graft-substitutes-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Visit Our Blog: http://zmrnewsnetwork.com | http://www.clickfeaturetech.com | https://prosampleresume.com
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://newszmr.com